Revolution Ebitda vs Reconciled Depreciation Analysis

RVMD Stock

USD 60.60 0.16 0.26%

Revolution Medicines financial indicator trend analysis is much more than just breaking down Revolution Medicines prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Revolution Medicines is a good investment. Please check the relationship between Revolution Medicines Ebitda and its Reconciled Depreciation accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.

Ebitda vs Reconciled Depreciation

Ebitda vs Reconciled Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Revolution Medicines Ebitda account and Reconciled Depreciation. At this time, the significance of the direction appears to have pay attention.

The correlation between Revolution Medicines' Ebitda and Reconciled Depreciation is -0.82. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Reconciled Depreciation in the same time period over historical financial statements of Revolution Medicines, assuming nothing else is changed. The correlation between historical values of Revolution Medicines' Ebitda and Reconciled Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Revolution Medicines are associated (or correlated) with its Reconciled Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Reconciled Depreciation has no effect on the direction of Ebitda i.e., Revolution Medicines' Ebitda and Reconciled Depreciation go up and down completely randomly.

Correlation Coefficient

-0.82

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Ebitda

Reconciled Depreciation

Most indicators from Revolution Medicines' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Revolution Medicines current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.At present, Revolution Medicines' Sales General And Administrative To Revenue is projected to slightly grow based on the last few years of reporting.

	2021	2022	2023	2024 (projected)
Interest Income	929K	9.2M	47.5M	49.9M
Net Interest Income	917K	9.2M	47.2M	49.5M

Interest Income Net Interest Income

Revolution Medicines fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other	Net Working Capital
Total Assets		0.88	0.97	1.0	0.01	0.88	0.95	-0.96	-0.98	0.99	0.98	0.82	0.11	0.02	1.0	0.87	0.79	0.9	1.0	0.97	0.98	0.99	0.95	1.0	0.08	1.0
Other Current Liab	0.88		0.95	0.88	-0.07	0.64	0.73	-0.94	-0.86	0.93	0.93	0.56	0.33	-0.15	0.89	0.68	0.46	0.63	0.9	0.94	0.82	0.86	0.74	0.89	-0.01	0.88
Total Current Liabilities	0.97	0.95		0.97	0.09	0.79	0.87	-0.96	-0.95	0.98	0.97	0.77	0.15	0.0	0.97	0.83	0.69	0.81	0.98	0.97	0.95	0.95	0.87	0.97	0.1	0.97
Total Stockholder Equity	1.0	0.88	0.97		-0.01	0.88	0.95	-0.96	-0.98	0.99	0.98	0.8	0.12	0.0	1.0	0.86	0.78	0.89	1.0	0.97	0.98	0.99	0.95	1.0	0.08	1.0
Other Liab	0.01	-0.07	0.09	-0.01		-0.12	-0.02	0.03	0.03	-0.03	-0.04	0.36	-0.23	0.26	-0.03	0.08	0.29	0.01	-0.01	-0.07	0.16	-0.02	-0.03	-0.03	0.18	-0.04
Net Tangible Assets	0.88	0.64	0.79	0.88	-0.12		0.97	-0.75	-0.91	0.82	0.8	0.83	-0.25	0.27	0.88	0.87	0.83	0.99	0.88	0.83	0.88	0.91	0.97	0.87	0.24	0.88
Property Plant And Equipment Net	0.95	0.73	0.87	0.95	-0.02	0.97		-0.84	-0.97	0.9	0.88	0.88	-0.13	0.24	0.94	0.9	0.88	0.98	0.94	0.9	0.95	0.96	1.0	0.94	0.09	0.94
Net Debt	-0.96	-0.94	-0.96	-0.96	0.03	-0.75	-0.84		0.92	-0.98	-1.0	-0.67	-0.36	0.21	-0.97	-0.76	-0.65	-0.75	-0.97	-0.97	-0.92	-0.96	-0.84	-0.97	0.0	-0.97
Retained Earnings	-0.98	-0.86	-0.95	-0.98	0.03	-0.91	-0.97	0.92		-0.97	-0.95	-0.84	-0.02	-0.15	-0.98	-0.9	-0.81	-0.92	-0.98	-0.97	-0.97	-0.98	-0.98	-0.98	-0.02	-0.98
Accounts Payable	0.99	0.93	0.98	0.99	-0.03	0.82	0.9	-0.98	-0.97		0.99	0.75	0.22	-0.06	0.99	0.82	0.71	0.83	0.99	0.98	0.96	0.98	0.9	0.99	0.02	0.99
Cash	0.98	0.93	0.97	0.98	-0.04	0.8	0.88	-1.0	-0.95	0.99		0.71	0.3	-0.15	0.99	0.78	0.69	0.8	0.98	0.98	0.94	0.98	0.88	0.99	0.01	0.99
Non Current Assets Total	0.82	0.56	0.77	0.8	0.36	0.83	0.88	-0.67	-0.84	0.75	0.71		-0.35	0.45	0.79	0.94	0.96	0.9	0.8	0.72	0.89	0.8	0.87	0.79	0.22	0.79
Non Currrent Assets Other	0.11	0.33	0.15	0.12	-0.23	-0.25	-0.13	-0.36	-0.02	0.22	0.3	-0.35		-0.88	0.15	-0.25	-0.26	-0.29	0.12	0.22	0.02	0.11	-0.12	0.15	-0.48	0.15
Other Assets	0.02	-0.15	0.0	0.0	0.26	0.27	0.24	0.21	-0.15	-0.06	-0.15	0.45	-0.88		-0.02	0.35	0.34	0.33	0.01	-0.03	0.12	-0.01	0.24	-0.02	0.08	-0.02
Cash And Short Term Investments	1.0	0.89	0.97	1.0	-0.03	0.88	0.94	-0.97	-0.98	0.99	0.99	0.79	0.15	-0.02		0.85	0.77	0.88	1.0	0.98	0.97	0.99	0.94	1.0	0.07	1.0
Common Stock Shares Outstanding	0.87	0.68	0.83	0.86	0.08	0.87	0.9	-0.76	-0.9	0.82	0.78	0.94	-0.25	0.35	0.85		0.89	0.9	0.86	0.8	0.89	0.85	0.9	0.85	0.2	0.85
Non Current Liabilities Total	0.79	0.46	0.69	0.78	0.29	0.83	0.88	-0.65	-0.81	0.71	0.69	0.96	-0.26	0.34	0.77	0.89		0.89	0.76	0.68	0.86	0.79	0.87	0.77	0.12	0.77
Capital Surpluse	0.9	0.63	0.81	0.89	0.01	0.99	0.98	-0.75	-0.92	0.83	0.8	0.9	-0.29	0.33	0.88	0.9	0.89		0.88	0.82	0.91	0.91	0.98	0.88	0.23	0.89
Other Current Assets	1.0	0.9	0.98	1.0	-0.01	0.88	0.94	-0.97	-0.98	0.99	0.98	0.8	0.12	0.01	1.0	0.86	0.76	0.88		0.98	0.98	0.99	0.94	1.0	0.09	1.0
Other Stockholder Equity	0.97	0.94	0.97	0.97	-0.07	0.83	0.9	-0.97	-0.97	0.98	0.98	0.72	0.22	-0.03	0.98	0.8	0.68	0.82	0.98		0.94	0.97	0.91	0.98	-0.06	0.97
Total Liab	0.98	0.82	0.95	0.98	0.16	0.88	0.95	-0.92	-0.97	0.96	0.94	0.89	0.02	0.12	0.97	0.89	0.86	0.91	0.98	0.94		0.97	0.95	0.98	0.1	0.97
Net Invested Capital	0.99	0.86	0.95	0.99	-0.02	0.91	0.96	-0.96	-0.98	0.98	0.98	0.8	0.11	-0.01	0.99	0.85	0.79	0.91	0.99	0.97	0.97		0.95	0.99	0.1	0.99
Property Plant And Equipment Gross	0.95	0.74	0.87	0.95	-0.03	0.97	1.0	-0.84	-0.98	0.9	0.88	0.87	-0.12	0.24	0.94	0.9	0.87	0.98	0.94	0.91	0.95	0.95		0.94	0.05	0.94
Total Current Assets	1.0	0.89	0.97	1.0	-0.03	0.87	0.94	-0.97	-0.98	0.99	0.99	0.79	0.15	-0.02	1.0	0.85	0.77	0.88	1.0	0.98	0.98	0.99	0.94		0.07	1.0
Non Current Liabilities Other	0.08	-0.01	0.1	0.08	0.18	0.24	0.09	0.0	-0.02	0.02	0.01	0.22	-0.48	0.08	0.07	0.2	0.12	0.23	0.09	-0.06	0.1	0.1	0.05	0.07		0.07
Net Working Capital	1.0	0.88	0.97	1.0	-0.04	0.88	0.94	-0.97	-0.98	0.99	0.99	0.79	0.15	-0.02	1.0	0.85	0.77	0.89	1.0	0.97	0.97	0.99	0.94	1.0	0.07

Click cells to compare fundamentals

Revolution Medicines Account Relationship Matchups

Revolution Medicines fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	220.5M	567.4M	738.0M	811.9M	2.1B	2.2B
Other Current Liab	14.4M	10.3M	(20.3M)	29.4M	74.7M	78.4M
Total Current Liabilities	43.1M	47.2M	18.9M	62.0M	143.9M	151.0M
Total Stockholder Equity	152.5M	474.7M	602.6M	685.2M	1.8B	1.9B
Other Liab	24.9M	16.6M	14.7M	7.3M	6.6M	6.3M
Net Tangible Assets	(229.2M)	399.1M	528.1M	611.8M	703.5M	738.7M
Property Plant And Equipment Net	7.1M	36.3M	71.2M	73.7M	100.0M	105.0M
Net Debt	(16.5M)	(71.6M)	(41.9M)	(97.2M)	(608.2M)	(577.8M)
Retained Earnings	(157.4M)	(265.5M)	(452.6M)	(701.3M)	(1.1B)	(1.1B)
Accounts Payable	11.4M	12.6M	14.1M	21.3M	61.8M	64.9M
Cash	16.7M	104.3M	108.5M	161.4M	696.1M	731.0M
Non Current Assets Total	86.5M	113.3M	160.9M	151.7M	209.3M	127.7M
Non Currrent Assets Other	(8.3M)	(19.1M)	(14.5M)	(23.4M)	7.0M	7.4M
Other Assets	2.8M	1.4M	2.5M	4.6M	1.0	0.95
Cash And Short Term Investments	122.8M	440.7M	577.1M	644.9M	1.9B	1.9B
Common Stock Shares Outstanding	59.0M	66.6M	72.8M	80.6M	113.1M	73.1M
Liabilities And Stockholders Equity	220.5M	567.4M	738.0M	811.9M	2.1B	2.2B
Non Current Liabilities Total	24.9M	45.5M	116.5M	64.8M	118.5M	65.5M
Capital Surpluse	1.3M	4.7M	740.1M	1.1B	1.2B	1.3B
Capital Lease Obligations	172K	32.7M	66.6M	64.2M	87.9M	92.3M
Other Current Assets	2.5M	7.0M	6.8M	10.6M	25.1M	26.3M
Other Stockholder Equity	4.7M	172.7M	317.6M	1.4B	3.0B	3.1B
Total Liab	68.0M	92.7M	135.4M	126.7M	262.4M	275.5M
Net Invested Capital	(152.6M)	474.7M	602.6M	685.2M	1.8B	1.9B
Property Plant And Equipment Gross	7.1M	36.3M	82.0M	88.2M	117.7M	123.6M
Total Current Assets	134.0M	454.1M	577.1M	660.2M	1.9B	2.0B
Accumulated Other Comprehensive Income	74K	116K	(376K)	(1.8M)	544K	571.2K
Non Current Liabilities Other	655K	38.1M	634K	301K	1.5M	1.4M
Net Working Capital	90.9M	406.9M	558.1M	598.2M	1.7B	1.8B
Property Plant Equipment	7.1M	8.9M	71.2M	73.7M	84.8M	89.0M
Short Long Term Debt Total	172K	32.7M	66.6M	64.2M	87.9M	46.2M
Current Deferred Revenue	17.1M	20.6M	18.9M	4.5M	4.0M	3.8M
Net Receivables	8.7M	6.4M	5.9M	4.7M	1.3M	1.2M
Capital Stock	305.1M	7K	8K	9K	16K	15.2K
Short Term Debt	172K	3.7M	6.2M	6.8M	7.4M	4.5M
Intangible Assets	62.0M	60.9M	59.9M	58.8M	57.7M	48.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
CRM	Salesforce
S	SentinelOne

When determining whether Revolution Medicines is a strong investment it is important to analyze Revolution Medicines' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revolution Medicines' future performance. For an informed investment choice regarding Revolution Stock, refer to the following important reports:

How To Invest In Revolution

Details

Is Revolution Stock a good investment?

Details

What is Revolution Medicines' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.

You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revolution Medicines. If investors know Revolution will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revolution Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.66)

Revenue Per Share

0.005

Quarterly Revenue Growth

(0.95)

Return On Assets

(0.29)

Return On Equity

(0.47)

The market value of Revolution Medicines is measured differently than its book value, which is the value of Revolution that is recorded on the company's balance sheet. Investors also form their own opinion of Revolution Medicines' value that differs from its market value or its book value, called intrinsic value, which is Revolution Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revolution Medicines' market value can be influenced by many factors that don't directly affect Revolution Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Revolution Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revolution Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revolution Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Revolution Ebitda vs Reconciled Depreciation Analysis

Ebitda vs Reconciled Depreciation

Ebitda vs Reconciled Depreciation Correlation Analysis

Correlation Coefficient

Ebitda

Reconciled Depreciation

Revolution Medicines fundamental ratios Correlations

Revolution Medicines Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Revolution Medicines fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Other Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity

Cash	- 1.0	Net Debt
Net Working Capital	- 0.98	Retained Earnings
Total Current Assets	- 0.98	Retained Earnings
Property Plant And Equipment Gross	- 0.98	Retained Earnings
Net Invested Capital	- 0.98	Retained Earnings
Other Current Assets	- 0.98	Retained Earnings